Boston Partners Sells 14,919 Shares of ZimVie Inc. (NASDAQ:ZIMV)

Boston Partners lessened its stake in shares of ZimVie Inc. (NASDAQ:ZIMV) by 44.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,541 shares of the company’s stock after selling 14,919 shares during the period. Boston Partners owned about 0.07% of ZimVie worth $259,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. SG Americas Securities LLC raised its position in ZimVie by 15.7% during the 4th quarter. SG Americas Securities LLC now owns 11,110 shares of the company’s stock valued at $155,000 after purchasing an additional 1,508 shares in the last quarter. EMC Capital Management raised its holdings in shares of ZimVie by 47.0% in the fourth quarter. EMC Capital Management now owns 13,802 shares of the company’s stock valued at $193,000 after acquiring an additional 4,414 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in ZimVie in the third quarter worth about $275,000. Bailard Inc. grew its holdings in ZimVie by 35.0% during the 4th quarter. Bailard Inc. now owns 21,194 shares of the company’s stock worth $296,000 after acquiring an additional 5,494 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in ZimVie during the 3rd quarter valued at about $470,000. Hedge funds and other institutional investors own 95.63% of the company’s stock.

ZimVie Trading Up 0.5 %

Shares of NASDAQ:ZIMV opened at $11.66 on Monday. The company has a market capitalization of $322.71 million, a PE ratio of -0.89 and a beta of 2.10. The company has a current ratio of 1.94, a quick ratio of 1.38 and a debt-to-equity ratio of 0.57. ZimVie Inc. has a 12-month low of $11.35 and a 12-month high of $22.40. The business’s fifty day simple moving average is $13.31 and its 200-day simple moving average is $14.20.

ZimVie (NASDAQ:ZIMV) last posted its earnings results on Wednesday, February 26th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. The company had revenue of $111.52 million for the quarter, compared to analyst estimates of $113.67 million. ZimVie had a positive return on equity of 2.90% and a negative net margin of 77.31%. As a group, equities research analysts predict that ZimVie Inc. will post 0.6 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of ZimVie in a research report on Thursday, March 13th.

ZimVie Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.